Paulo M. Hoff
Paulo M. Hoff
Professor de Oncologia, Faculdade de Medicina, Universidade de Sao Paulo
Verified email at
Cited by
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a …
PM Hoff, R Ansari, G Batist, J Cox, W Kocha, M Kuperminc, J Maroun, ...
Journal of Clinical Oncology 19 (8), 2282-2292, 2001
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases
N Vauthey, T Pawlik, D Ribero, TT Wu, D Zorzi, P Hoff, H Xiong, C Eng, ...
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
MA Kouvaraki, JA Ajani, P Hoff, R Wolff, DB Evans, R Lozano, JC Yao
Journal of Clinical Oncology 22 (23), 4762-4771, 2004
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin
J Cassidy, C Twelves, E Van Cutsem, P Hoff, E Bajetta, M Boyer, R Bugat, ...
Annals of oncology 13 (4), 566-575, 2002
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines
AD Yang, F Fan, ER Camp, G van Buren, W Liu, R Somcio, MJ Gray, ...
Clinical cancer research 12 (14), 4147-4153, 2006
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
LB Saltz, HJ Lenz, HL Kindler, HS Hochster, S Wadler, PM Hoff, ...
Journal of Clinical Oncology 25 (29), 4557-4561, 2007
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
E Van Cutsem, PM Hoff, P Harper, RM Bukowski, D Cunningham, ...
British journal of cancer 90 (6), 1190-1197, 2004
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …
S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ...
Journal of clinical oncology 28 (3), 453, 2010
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b
JC Yao, A Phan, PM Hoff, HX Chen, C Charnsangavej, SCJ Yeung, ...
Journal of Clinical Oncology 26 (8), 1316-1323, 2008
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
JY Douillard, PM Hoff, JR Skillings, P Eisenberg, N Davidson, P Harper, ...
Journal of Clinical Oncology 20 (17), 3605-3616, 2002
Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal …
JR Hecht, YJ Bang, SK Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 34 (5), 443-451, 2016
Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer
NA Janjan, C Crane, BW Feig, K Cleary, R Dubrow, S Curley, JN Vauthey, ...
American journal of clinical oncology 24 (2), 107-112, 2001
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics
L Claret, P Girard, PM Hoff, E Van Cutsem, KP Zuideveld, K Jorga, ...
Journal of Clinical Oncology 27 (25), 4103-4108, 2009
Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
LB Saltz, HJ Lenz, H Hochster, S Wadler, P Hoff, N Kemeny, E Hollywood, ...
Journal of Clinical Oncology 23 (16_suppl), 3508-3508, 2005
Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients
M Bonnen, C Crane, JN Vauthey, J Skibber, ME Delclos, ...
International Journal of Radiation Oncology* Biology* Physics 60 (4), 1098-1105, 2004
Potential regional differences for the tolerability profiles of fluoropyrimidines
DG Haller, J Cassidy, SJ Clarke, D Cunningham, E Van Cutsem, PM Hoff, ...
Journal of Clinical Oncology 26 (13), 2118-2123, 2008
Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial
MS Avila, SM Ayub-Ferreira, MR de Barros Wanderley, F das Dores Cruz, ...
Journal of the American College of Cardiology 71 (20), 2281-2290, 2018
The system can't perform the operation now. Try again later.
Articles 1–20